130 related articles for article (PubMed ID: 31720667)
1. Real-time monitoring of etoposide prodrug activated by hydrogen peroxide with improved safety.
Zhu J; Chen J; Song D; Zhang W; Guo J; Cai G; Ren Y; Wan C; Kong L; Yu W
J Mater Chem B; 2019 Dec; 7(47):7548-7557. PubMed ID: 31720667
[TBL] [Abstract][Full Text] [Related]
2. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
3. An activatable prodrug for the treatment of metastatic tumors.
Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
[TBL] [Abstract][Full Text] [Related]
4. Etoposide phosphate, the water soluble prodrug of etoposide.
Witterland AH; Koks CH; Beijnen JH
Pharm World Sci; 1996 Oct; 18(5):163-70. PubMed ID: 8933576
[TBL] [Abstract][Full Text] [Related]
5. A dithiocarbamate-based H
Pan Q; Zhang B; Peng X; Wan S; Luo K; Gao W; Pu Y; He B
Chem Commun (Camb); 2019 Nov; 55(92):13896-13899. PubMed ID: 31675022
[TBL] [Abstract][Full Text] [Related]
6. Polymersome nanoreactors with tumor pH-triggered selective membrane permeability for prodrug delivery, activation, and combined oxidation-chemotherapy.
Mukerabigwi JF; Yin W; Zha Z; Ke W; Wang Y; Chen W; Japir AAMM; Wang Y; Ge Z
J Control Release; 2019 Jun; 303():209-222. PubMed ID: 31026547
[TBL] [Abstract][Full Text] [Related]
7. In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer.
Zhang D; Yang J; Guan J; Yang B; Zhang S; Sun M; Yang R; Zhang T; Zhang R; Kan Q; Zhang H; He Z; Shang L; Sun J
Biomater Sci; 2018 Aug; 6(9):2360-2374. PubMed ID: 30019051
[TBL] [Abstract][Full Text] [Related]
8. Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemotherapy.
Li J; Ke W; Wang L; Huang M; Yin W; Zhang P; Chen Q; Ge Z
J Control Release; 2016 Mar; 225():64-74. PubMed ID: 26806789
[TBL] [Abstract][Full Text] [Related]
9. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
10. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
Lange B; Schroeder U; Huebener N; Jikai J; Wenkel J; Strandsby A; Wrasidlo W; Gaedicke G; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):225-30. PubMed ID: 12880986
[TBL] [Abstract][Full Text] [Related]
11. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.
Jikai J; Shamis M; Huebener N; Schroeder U; Wrasidlo W; Wenkel J; Lange B; Gaedicke G; Shabat D; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):219-24. PubMed ID: 12880985
[TBL] [Abstract][Full Text] [Related]
13. A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy.
Li SY; Liu LH; Jia HZ; Qiu WX; Rong L; Cheng H; Zhang XZ
Chem Commun (Camb); 2014 Oct; 50(80):11852-5. PubMed ID: 25145493
[TBL] [Abstract][Full Text] [Related]
14. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug.
Schmidt F; Monneret C
Bioorg Med Chem; 2003 May; 11(10):2277-83. PubMed ID: 12713838
[TBL] [Abstract][Full Text] [Related]
15. Anticancer nano-prodrugs with drug release triggered by intracellular dissolution and hydrogen peroxide response.
Shibata A; Koseki Y; Tanita K; Kitajima S; Oka K; Maruoka K; Suzuki R; Thi Ngoc Dao A; Kasai H
Chem Commun (Camb); 2024 Jun; 60(50):6427-6430. PubMed ID: 38829169
[TBL] [Abstract][Full Text] [Related]
16. Allyl phenyl selenides as H
Yang XY; Yuan B; Xiong H; Zhao Y; Wang L; Zhang SQ; Mao S
Bioorg Chem; 2022 Dec; 129():106154. PubMed ID: 36137311
[TBL] [Abstract][Full Text] [Related]
17. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
[TBL] [Abstract][Full Text] [Related]
18. 10-Boronic acid substituted camptothecin as prodrug of SN-38.
Wang L; Xie S; Ma L; Chen Y; Lu W
Eur J Med Chem; 2016 Jun; 116():84-89. PubMed ID: 27060760
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy.
Han J; Michel AR; Lee HS; Kalscheuer S; Wohl A; Hoye TR; McCormick AV; Panyam J; Macosko CW
Mol Pharm; 2015 Dec; 12(12):4329-35. PubMed ID: 26505116
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.
Christodoulou MS; Zunino F; Zuco V; Borrelli S; Comi D; Fontana G; Martinelli M; Lorens JB; Evensen L; Sironi M; Pieraccini S; Dalla Via L; Gia OM; Passarella D
ChemMedChem; 2012 Dec; 7(12):2134-43. PubMed ID: 23086693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
